Genome editing at the crossroads of delivery, specificity, and fidelity

Trends in Biotechnology

Volumn 33, Issue 5, 2015, Pages 280-291

  Maggio, Ignazio ^a   Gonçalves, Manuel A F V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Delivery systems; Designer nucleases; Donor DNA; Gene targeting; Genome editing; High fidelity

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DESIGN; DNA; MAMMALS;

DELIVERY SYSTEMS; DESIGNER NUCLEASES; GENE TARGETING; GENOMIC SEQUENCE; HIGH-FIDELITY; INCREMENTAL IMPROVEMENTS; MAMMALIAN TARGET; STATE OF THE ART;

GENES;

DESIGNER NUCLEASE; DNA; NUCLEASE; UNCLASSIFIED DRUG; VIRUS VECTOR; DEOXYRIBONUCLEASE;

DNA EDITING; DNA MODIFICATION; DNA TEMPLATE; GENE CONSTRUCT; GENE INACTIVATION; GENE SEQUENCE; GENE TARGETING; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSFECTION; GENOME EDITING; HUMAN; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; GENOMICS; PHYSIOLOGY; PROCEDURES; PROTEIN ENGINEERING; STANDARDS; TRENDS;

MAMMALIA;

ANIMALS; DEOXYRIBONUCLEASES; DNA; GENE TARGETING; GENETIC ENGINEERING; GENOMICS; HUMANS; MODELS, GENETIC; PROTEIN ENGINEERING;

EID: 84928054835     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.02.011     Document Type: Review

References (120)

1. Gaj T., et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
2. Segal D.J., Meckler J.F. Genome engineering at the dawn of the golden age. Annu. Rev. Genomics Hum. Genet. 2013, 14:135-158.
3. Lukacsovich T., et al. Repair of a specific double-strand break generated within a mammalian chromosome by yeast endonuclease I-SceI. Nucleic Acids Res. 1994, 22:5649-5657.
4. Rouet P., et al. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6064-6068.
5. Tebas P., et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370:901-910.
6. Porteus M.H., Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003, 300:763.
7. Urnov F.D., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.
8. Shi N.Q., et al. A survey on 'Trojan Horse' peptides: opportunities, issues and controlled entry to 'Troy'. J. Control Release 2014, 194C:53-70.
9. Kuhn A.N., et al. mRNA as a versatile tool for exogenous protein expression. Curr. Gene Ther. 2012, 12:347-361.
10. Wadia J.S., et al. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004, 10:310-315.
11. Gaj T., et al. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 2012, 9:805-807.
12. Ru R., et al. Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell. Regen. (Lond.) 2013, 2:5.
13. Liu J., et al. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS ONE 2014, 9:e85755.
14. Ramakrishna S., et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 2014, 24:1020-1027.
15. Chen Z., et al. Receptor-mediated delivery of engineered nucleases for genome modification. Nucleic Acids Res. 2013, 41:e182.
16. Kim S., et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014, 24:1012-1019.
17. Lin S., et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 2014, 15:4.
18. Zuris J.A., et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 2014, 33:73-80.
19. Sahin U., et al. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 2014, 13:759-780.
20. Genovese P., et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014, 510:235-240.
21. Cai Y., et al. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. Elife 2014, 3:e01911.
22. Mock U., et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci. Rep. 2014, 4:6409.
23. Lombardo A., et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 2007, 25:1298-1306.
24. Gabriel R., et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 2011, 29:816-823.
25. Lombardo A., et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 2011, 8:861-869.
26. Provasi E., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012, 18:807-815.
27. Benabdallah B.F., et al. Targeted gene addition of microdystrophin in mice skeletal muscle via human myoblast transplantation. Mol. Ther. Nucleic Acids 2013, 2:e68.
28. Coluccio A., et al. Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol. Ther. 2013, 21:1695-1704.
29. Joglekar A.V., et al. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol. Ther. 2013, 21:1705-1717.
30. Lei Y., et al. Gene editing of human embryonic stem cells via an engineered baculoviral vector carrying zinc-finger nucleases. Mol. Ther. 2011, 19:942-950.
31. Zhu H., et al. Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res. 2013, 41:e180.
32. Lau C-H., et al. Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. Mol. Ther. Methods Clin. Dev. 2014, 1:14050.
33. + T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26:808-816.
34. Holkers M., et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2013, 41:e63.
35. Ding Q., et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 2014, 115:488-492.
36. Holkers M., et al. Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods 2014, 69:179-187.
37. Holkers M., et al. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat. Methods 2014, 11:1051-1057.
38. Maddalo D., et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 2014, 516:423-427.
39. Maggio I., et al. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci. Rep. 2014, 4:5105.
40. Suzuki K., et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 2014, 15:31-36.
41. Zhang S., et al. TALEN-mediated somatic mutagenesis in murine models of cancer. Cancer Res. 2014, 74:5311-5321.
42. Zhang W., et al. Targeted genome correction by a single adenoviral vector simultaneously carrying an inducible zinc finger nuclease and a donor template. J. Biotechnol. 2014, 188C:1-6.
43. Saydaminova K., et al. Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Mol. Ther. Methods Clin. Dev. 2015, 1:14057.
44. Li H., et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011, 475:217-221.
45. Händel E.M., et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. Hum. Gene Ther. 2012, 23:321-329.
46. Asuri P., et al. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol. Ther. 2012, 20:329-338.
47. Anguela X.M., et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 2013, 122:3283-3287.
48. Ellis B.L., et al. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther. 2013, 20:35-42.
49. Rahman S.H., et al. The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting. Hum. Gene Ther. 2013, 24:67-77.
50. Platt R.J., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014, 159:440-455.
51. Swiech L., et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 2014, 33:102-106.
52. Pelascini L.P., et al. Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. Hum. Gene Ther. Methods 2013, 24:399-411.
53. Kantor B., et al. Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18786-18791.
54. Pelascini L.P., et al. Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum. Gene Ther. 2013, 24:78-96.
55. Yang L., et al. Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 2013, 41:9049-9061.
56. Pruett-Miller S.M., et al. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet. 2009, 5:e1000376.
57. Cornu T.I., et al. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol. Ther. 2008, 16:352-358.
58. Urnov F.D., et al. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11:636-646.
59. Doyon Y., et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 2011, 8:74-79.
60. Szczepek M., et al. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 2007, 25:786-793.
61. Händel E.M., et al. Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity. Mol Ther. 2009, 17:104-111.
62. Wilson K.A., et al. Expanding the repertoire of target sites for zinc finger nuclease-mediated genome modification. Mol. Ther. Nucleic Acids 2013, 2:e88.
63. Mussolino C., et al. TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res. 2014, 2:6762-6773.
64. Cade L., et al. Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res. 2012, 40:8001-8010.
65. Boissel S., et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 2014, 42:2591-2601.
66. Lin J., et al. Creating a monomeric endonuclease TALE-I-SceI with high specificity and low genotoxicity in human cells. Nucleic Acids Res. 2014, 43:1112-1122.
67. Reyon D., et al. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 2012, 30:460-465.
68. Guilinger J.P., et al. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods 2014, 11:429-435.
69. Juillerat A., et al. Comprehensive analysis of the specificity of transcription activator-like effector nucleases. Nucleic Acids Res. 2014, 42:5390-5402.
70. Cradick T.J., et al. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013, 41:9584-9592.
71. Fu Y., et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31:822-826.
72. Hsu P.D., et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31:827-832.
73. Pattanayak V., et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 2013, 31:839-843.
74. Smith C., et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 2014, 15:12-13.
75. Veres A., et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 2014, 15:27-30.
76. Mali P., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 2013, 31:833-838.
77. Ran F.A., et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154:1380-1389.
78. Fu Y., et al. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 2014, 32:279-284.
79. Guilinger J.P., et al. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014, 32:577-582.
80. Tsai S.Q., et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 2014, 32:569-576.
81. Esvelt K.M., et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 2013, 10:1116-1121.
82. Frock R.L., et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 2014, 33:179-186.
83. Gabriel R., et al. Mapping the precision of genome editing. Nat. Biotechnol. 2015, 33:150-152.
84. Hendel A., et al. Quantifying on- and off-target genome editing. Trends Biotechnol. 2015, 33:132-140.
85. Kass E.M., Jasin M. Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett. 2010, 584:3703-3708.
86. Lee G.S., et al. RAG proteins shepherd double-strand breaks to a specific pathway, suppressing error-prone repair, but RAG nicking initiates homologous recombination. Cell 2004, 117:171-184.
87. McConnell Smith A., et al. Generation of a nicking enzyme that stimulates site-specific gene conversion from the I-AniI LAGLIDADG homing endonuclease. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:5099-5104.
88. van Nierop G.P., et al. Stimulation of homology-directed gene targeting at an endogenous human locus by a nicking endonuclease. Nucleic Acids Res. 2009, 37:5725-5736.
89. Mali P., et al. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
90. Wang J., et al. Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res. 2012, 22:1316-1326.
91. Ramirez C.L., et al. Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res. 2012, 40:5560-5568.
92. Beurdeley M., et al. Compact designer TALENs for efficient genome engineering. Nat. Commun. 2013, 4:1762.
93. Gabsalilow L., et al. Site- and strand-specific nicking of DNA by fusion proteins derived from MutH and I-SceI or TALE repeats. Nucleic Acids Res. 2013, 41:e83.
94. Bishop J.O., Smith P. Mechanism of chromosomal integration of microinjected DNA. Mol. Biol. Med. 1989, 6:283-298.
95. Hockemeyer D., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 2011, 29:731-734.
96. Chen F., et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat. Methods 2011, 8:753-755.
97. Radecke S., et al. Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. Mol. Ther. 2010, 18:743-753.
98. Stewart J.A., et al. Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation. Mutat. Res. 2012, 730:12-19.
99. Capecchi M.R. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat. Rev. Genet. 2005, 6:507-512.
100. Maetzig T., et al. Gammaretroviral vectors: biology, technology and application. Viruses 2011, 3:677-713.
101. Biasco L., et al. Retroviral integrations in gene therapy trials. Mol. Ther. 2012, 20:709-716.
102. Schambach A., et al. Biosafety features of lentiviral vectors. Hum. Gene Ther. 2013, 24:132-142.
103. Schröder A.R., et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110:521-529.
104. Wu X., et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
105. Matreyek K.A., Engelman A. Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses 2013, 5:2483-2511.
106. Baum C. Data vs. dogma: HIV-1 integrations driving clonal selection. Mol Ther. 2014, 22:1557-1558.
107. Aiuti A., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341:1233151.
108. Biffi A., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341:1233158.
109. Ivics Z., et al. Transposon-mediated genome manipulation in vertebrates. Nat. Methods 2009, 6:415-422.
110. Turan S., Bode J. Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications. FASEB J. 2011, 25:4088-4107.
111. Recchia A., Mavilio F. Site-specific integration by the adeno-associated virus rep protein. Curr. Gene Ther. 2011, 11:399-405.
112. González-Prieto C., et al. HUH site-specific recombinases for targeted modification of the human genome. Trends Biotechnol. 2013, 31:305-312.
113. Marcaida M.J., et al. Homing endonucleases: from basics to therapeutic applications. Cell. Mol. Life Sci. 2010, 67:727-748.
114. Gonçalves M.A.F.V., et al. Rapid and sensitive lentivirus vector-based conditional gene expression assay to monitor and quantify cell fusion activity. PLoS ONE 2010, 5:e10954.
115. Kim Y.G., et al. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1156-1160.
116. Gaj T., Barbas C.F. Genome engineering with custom recombinases. Methods Enzymol. 2014, 546:79-91.
117. Redondo P., et al. Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature 2008, 456:107-111.
118. Philpott N.J., Thrasher A.J. Use of nonintegrating lentiviral vectors for gene therapy. Hum. Gene Ther. 2007, 18:483-489.
119. Gonçalves M.A.F.V., de Vries A.A.F. Adenovirus: from foe to friend. Rev. Med. Virol. 2006, 16:167-186.
120. Gonçalves M.A.F.V. Adeno-associated virus: from defective virus to effective vector. Virol. J. 2005, 2:43.